Payment overview · 2025
General Payments
$10,148.82
10 reported records · 6 companies
Healthcare provider profile · identity verified
Nathaniel T Marchetti, DO
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · PHILADELPHIA, PA · NPI 1285622233
Verified facts
What the public records show
CMS Open Payments records show Nathaniel T Marchetti, DO received $10,148.82 in general payments during 2025 across 10 reported records.
AstraZeneca Pharmaceuticals LP accounted for 43.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Symbicort by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Privigen by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $4,432.50 | 43.7% | 4 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $2,110.72 | 20.8% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $2,043.22 | 20.1% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $1,500.00 | 14.8% | 1 | 2025 |
| Endovascular Engineering Inc. | Unresolved — no canonical attribution shown | $43.55 | 0.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.83 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,383.22 | 3 |
| Consulting Fee | $3,592.50 | 3 |
| Travel and Lodging | $1,946.75 | 1 |
| Food and Beverage | $226.35 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Zemaira Normalized: zemaira |
Biological | CSL Behring | $2,043.22 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $1,500.00 | 1 | 2025 |
Source payment records
|
|||||
| Helo Thrombectomy System Normalized: helo thrombectomy system |
Device | Endovascular Engineering Inc. | $43.55 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
59 | 16 |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 506 | 145 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 351 | 63 |
| Azithromycin | Azithromycin | 343 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 327 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 294 | 58 |
| Atovaquone | Atovaquone | 219 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 176 | 37 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 171 | 35 |
| Ofev | Nintedanib Esylate | 161 | 21 |
| Valganciclovir Hcl | Valganciclovir Hcl | 158 | 32 |
| Tacrolimus | Tacrolimus | 133 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 24 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 108 | 27 |
| Spiriva Respimat | Tiotropium Bromide | 106 | 28 |
| Gabapentin | Gabapentin | 89 | 19 |
| Furosemide | Furosemide | 82 | 24 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 72 | 22 |
| Eliquis | Apixaban | 72 | 17 |
| Dupixent Pen | Dupilumab | 65 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 63 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 59 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 55 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 11 |
| Levofloxacin | Levofloxacin | 53 | 37 |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | 11 |
| Potassium Chloride | Potassium Chloride | 49 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 48 | 12 |
| Atorvastatin Calcium | Atorvastatin Calcium | 46 | 15 |
| Tyvaso Dpi | Treprostinil | 43 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 41 | suppressed |
| Famotidine | Famotidine | 38 | suppressed |
| Pirfenidone | Pirfenidone | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | suppressed |
| Prevymis | Letermovir | 35 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Carvedilol | Carvedilol | 33 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 23 |
| Rifampin | Rifampin | 27 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 27 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 25 | suppressed |
| Nucala | Mepolizumab | 25 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Omeprazole | Omeprazole | 22 | suppressed |
| Ambrisentan | Ambrisentan | 20 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 20 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 17 | suppressed |
| Losartan Potassium | Losartan Potassium | 17 | suppressed |
| Sirolimus | Sirolimus | 17 | suppressed |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 15 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 14 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Xolair | Omalizumab | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Nulojix | Belatacept | 12 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Metformin Hcl | Metformin Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $10,148.82 · 10 records | AstraZeneca Pharmaceuticals LP | Helo Thrombectomy System, INSPIRE, Ohtuvayre, Zemaira | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error